---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-023265"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2025-06-23T23:59:59+00:00"
generated_at: "2026-05-18T23:23:43.857142+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Opus Genetics gets up to $2M non-dilutive funding from RD Fund for MERTK gene therapy program

## Summary
- Up to $2 million non-dilutive funding from RD Fund (Foundation Fighting Blindness) for OPGx-MERTK preclinical program.
- OPGx-MERTK targets retinitis pigmentosa caused by MERTK gene mutations; no approved therapies exist.
- Funding expected to support IND-enabling studies and advance gene therapy pipeline for inherited retinal diseases.
- Cash runway extended into second half of fiscal year 2026, based on current projections.

## SEC filing metadata
- accession: 0001140361-25-023265
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2025-06-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036125023265/0001140361-25-023265-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036125023265/ef20050882_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-023265
- JSON: https://secwatch.observer/filing/0001140361-25-023265.json
- Plain text: https://secwatch.observer/filing/0001140361-25-023265.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.